LAPS

Long-term Antipsychotic Pediatric Safety Trial (LAPS)

Summary

The primary objective of this 2-year, prospective observational study is to evaluate the long-term weight gain associated with either of two mono-antipsychotic therapies, risperidone or aripiprazole, in children aged 3-17 years. The study cohort will include ~350 children treated with risperidone at the time of enrollment and ~350 children treated with aripiprazole at the time of enrollment. The treated participants’ personal physicians will prescribe their medications over the course of the study. Study data will also provide information about the potential metabolic and neuromotor long-term health effects of pediatric exposure to risperidone and aripiprazole. Since some participants may stop treatment with risperidone or aripiprazole or switch to a different antipsychotic, the study may provide information about the persistence of adverse effects after risperidone or aripiprazole discontinuation or with other second generation antipsychotics.

Publications

    OVERVIEW

    Status:
    Enrolling

    ClinicalTrials.gov identifier:
    NCT03522168

    Principal Investigator:
    Linmarie Sikich, MD, MPH
    Duke Department of Psychiatry and Behavioral Sciences; Duke Center for Autism and Brain Development

    NEWS

    • First site activated for LAPS study on antipsychotic use in children The first site has been activated for the Long-term Antipsychotic Pediatric Safety (LAPS) Trial, which aims to determine the safety of long-term antipsychotic treatments in children. Dr. Ahmed Elmaadawi’s was the first site activated on Tuesday, Dec. 11. Dr. Elmaadawi is the director of the Interventional Psychiatry Program at Beacon Health System in South Bend, ...